{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:31:23Z","timestamp":1787045483863,"version":"build-2736575974"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41401-026-01858-x","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:21:58Z","timestamp":1780885318000},"page":"2653-2667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time-resolved proteomic and phosphoproteomic analysis reveals convergent and divergent biological perturbations induced by FDA-approved CDK4\/6 inhibitors in hormone receptor-positive breast cancers"],"prefix":"10.1038","volume":"47","author":[{"given":"Shi-yu","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-hui","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo-yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-xi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-hui","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-long","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-jia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-yu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-ting","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"1858_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1858_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.","journal-title":"Nature"},{"key":"1858_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"1858_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","volume":"32","author":"LM Gelbert","year":"2014","unstructured":"Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine. Investig New Drugs. 2014;32:825\u201337.","journal-title":"Investig New Drugs"},{"key":"1858_CR5","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427\u201338.","journal-title":"Mol Cancer Ther"},{"key":"1858_CR6","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1038\/onc.2010.154","volume":"29","author":"JL Dean","year":"2010","unstructured":"Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29:4018\u201332.","journal-title":"Oncogene"},{"key":"1858_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022;22:356\u201372.","journal-title":"Nat Rev Cancer"},{"key":"1858_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209\u201319.","journal-title":"N Engl J Med"},{"key":"1858_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339.","journal-title":"Lancet Oncol"},{"key":"1858_CR10","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465\u201372.","journal-title":"J Clin Oncol"},{"key":"1858_CR11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904\u201315.","journal-title":"Lancet Oncol"},{"key":"1858_CR12","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875\u201384.","journal-title":"J Clin Oncol"},{"key":"1858_CR13","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346.","journal-title":"J Clin Oncol"},{"key":"1858_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105570","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, et al. Real-world progression-free survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR-positive\/HER2-negative metastatic breast cancer in United States routine clinical practice. ESMO Open. 2025;10:105570.","journal-title":"ESMO Open"},{"key":"1858_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial. J Clin Oncol. 2025;43:1101\u201312.","journal-title":"J Clin Oncol"},{"key":"1858_CR16","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023;41:4004\u201313.","journal-title":"J Clin Oncol"},{"key":"1858_CR17","doi-asserted-by":"crossref","unstructured":"Dickler MN, Tolaney SM, Rugo HS, Cort\u00e9s J, Di\u00e9ras V, Patt D, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2- metastatic breast cancer. Clin Cancer Res. 2017;23:5218\u201324.","DOI":"10.1158\/1078-0432.CCR-17-0754"},{"key":"1858_CR18","doi-asserted-by":"crossref","unstructured":"Marra A, Curigliano G. Are all cyclin-dependent kinases 4\/6 inhibitors created equal? NPJ Breast Cancer. 2019;5:27.","DOI":"10.1038\/s41523-019-0121-y"},{"key":"1858_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","volume":"26","author":"M Hafner","year":"2019","unstructured":"Hafner M, Mills CE, Subramanian K, Chen C, Chung M, Boswell SA, et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity. Cell Chem Biol. 2019;26:1067\u201380.e8.","journal-title":"Cell Chem Biol"},{"key":"1858_CR20","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","volume":"15","author":"P Chen","year":"2016","unstructured":"Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, et al. Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther. 2016;15:2273\u201381.","journal-title":"Mol Cancer Ther"},{"key":"1858_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/oncolo\/oyac138","volume":"27","author":"SA Wander","year":"2022","unstructured":"Wander SA, O\u2019Brien N, Litchfield LM, O\u2019Dea D, Morato Guimaraes C, Slamon DJ, et al. Targeting CDK4 and 6 in cancer therapy: emerging preclinical insights related to abemaciclib. Oncologist. 2022;27:811\u201321.","journal-title":"Oncologist"},{"key":"1858_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/1535-7163.MCT-18-0877","volume":"18","author":"JCM Uitdehaag","year":"2019","unstructured":"Uitdehaag JCM, Kooijman JJ, de Roos JADM, Prinsen MBW, Dylus J, Willemsen-Seegers N, et al. Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017. Mol Cancer Ther. 2019;18:470\u201381.","journal-title":"Mol Cancer Ther"},{"key":"1858_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/1541-7786.MCR-17-0468","volume":"16","author":"EM Cousins","year":"2018","unstructured":"Cousins EM, Goldfarb D, Yan F, Roques J, Darr D, Johnson GL, et al. Competitive kinase enrichment proteomics reveals that abemaciclib inhibits GSK3\u03b2 and activates WNT signaling. Mol Cancer Res. 2018;16:333\u201344.","journal-title":"Mol Cancer Res"},{"key":"1858_CR24","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/med.21769","volume":"41","author":"D Hendrychov\u00e1","year":"2021","unstructured":"Hendrychov\u00e1 D, Jorda R, Kry\u0161tof V. How selective are clinical CDK4\/6 inhibitors? Med Res Rev. 2021;41:1578\u201398.","journal-title":"Med Res Rev"},{"key":"1858_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"1858_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","volume":"20","author":"MM Attwood","year":"2021","unstructured":"Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schi\u00f6th HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20:839\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"1858_CR27","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-13-1610","volume":"20","author":"CM Lovly","year":"2014","unstructured":"Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res. 2014;20:2249\u201356.","journal-title":"Clin Cancer Res"},{"key":"1858_CR28","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.O111.016717","volume":"11","author":"LC Gillet","year":"2012","unstructured":"Gillet LC, Navarro P, Tate S, R\u00f6st H, Selevsek N, Reiter L, et al. Targeted data extraction of the MS\/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;11:O111.016717.","journal-title":"Mol Cell Proteomics"},{"key":"1858_CR29","doi-asserted-by":"crossref","unstructured":"Kumar L, Futschik ME. Mfuzz: a software package for soft clustering of microarray data. Bioinformation. 2007;2:5\u20137.","DOI":"10.6026\/97320630002005"},{"key":"1858_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1074\/mcp.TIR118.000943","volume":"18","author":"K Krug","year":"2019","unstructured":"Krug K, Mertins P, Zhang B, Hornbeck P, Raju R, Ahmad R, et al. A curated resource for phosphosite-specific signature analysis. Mol Cell Proteom. 2019;18:576\u201393.","journal-title":"Mol Cell Proteom"},{"key":"1858_CR31","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1093\/bioinformatics\/btx415","volume":"33","author":"DD Wiredja","year":"2017","unstructured":"Wiredja DD, Koyut\u00fcrk M, Chance MR. The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics. Bioinformatics. 2017;33:3489\u201391.","journal-title":"Bioinformatics"},{"key":"1858_CR32","doi-asserted-by":"publisher","first-page":"D433","DOI":"10.1093\/nar\/gky1159","volume":"47","author":"PV Hornbeck","year":"2019","unstructured":"Hornbeck PV, Kornhauser JM, Latham V, Murray B, Nandhikonda V, Nord A, et al. 15 years of PhosphoSitePlus\u00ae: integrating post-translationally modified sites, disease variants and isoforms. Nucleic Acids Res. 2019;47:D433\u201341.","journal-title":"Nucleic Acids Res"},{"key":"1858_CR33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2006.09.026","volume":"127","author":"JV Olsen","year":"2006","unstructured":"Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006;127:635\u201348.","journal-title":"Cell"},{"key":"1858_CR34","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.molcel.2018.11.017","volume":"73","author":"A Arif","year":"2019","unstructured":"Arif A, Jia J, Willard B, Li X, Fox PL. Multisite phosphorylation of S6K1 directs a kinase phospho-code that determines substrate selection. Mol Cell. 2019;73:446\u201357.e6.","journal-title":"Mol Cell"},{"key":"1858_CR35","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41586-025-09545-3","volume":"647","author":"Z Cui","year":"2025","unstructured":"Cui Z, Esposito A, Napolitano G, Ballabio A, Hurley JH. Structural basis for mTORC1 activation on the lysosomal membrane. Nature. 2025;647:536\u201343.","journal-title":"Nature"},{"key":"1858_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32515-6","volume":"13","author":"E Ratto","year":"2022","unstructured":"Ratto E, Chowdhury SR, Siefert NS, Schneider M, Wittmann M, Helm D, et al. Direct control of lysosomal catabolic activity by mTORC1 through regulation of V-ATPase assembly. Nat Commun. 2022;13:4848.","journal-title":"Nat Commun"},{"key":"1858_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41556-018-0244-7","volume":"21","author":"RE Lawrence","year":"2019","unstructured":"Lawrence RE, Zoncu R. The lysosome as a cellular centre for signalling, metabolism and quality control. Nat Cell Biol. 2019;21:133\u201342.","journal-title":"Nat Cell Biol"},{"key":"1858_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64800-5","volume":"16","author":"Y Zhi","year":"2025","unstructured":"Zhi Y, Zhang T, Lu D, Lin S, Su H, Wu Y, et al. Lysosomal and mTORC1 signaling dysregulation underpin the pathology of spastic paraplegia type 80. Nat Commun. 2025;16:9833.","journal-title":"Nat Commun"},{"key":"1858_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.mam.2006.08.005","volume":"27","author":"EL Eskelinen","year":"2006","unstructured":"Eskelinen EL. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol Aspects Med. 2006;27:495\u2013502.","journal-title":"Mol Aspects Med"},{"key":"1858_CR40","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nrm2272","volume":"8","author":"M Forgac","year":"2007","unstructured":"Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007;8:917\u201329.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1858_CR41","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1242\/jcs.091181","volume":"126","author":"S Aits","year":"2013","unstructured":"Aits S, J\u00e4\u00e4ttel\u00e4 M. Lysosomal cell death at a glance. J Cell Sci. 2013;126:1905\u201312.","journal-title":"J Cell Sci"},{"key":"1858_CR42","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/tra.12613","volume":"19","author":"F Wang","year":"2018","unstructured":"Wang F, G\u00f3mez-Sintes R, Boya P. Lysosomal membrane permeabilization and cell death. Traffic. 2018;19:918\u201331.","journal-title":"Traffic"},{"key":"1858_CR43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1126\/science.adg1955","volume":"383","author":"P Sharma","year":"2024","unstructured":"Sharma P, Zhang X, Ly K, Kim JH, Wan Q, Kim J, et al. Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape. Science. 2024;383:190\u2013200.","journal-title":"Science"},{"key":"1858_CR44","doi-asserted-by":"publisher","first-page":"31583","DOI":"10.1074\/jbc.M102736200","volume":"276","author":"F Ciaffoni","year":"2001","unstructured":"Ciaffoni F, Salvioli R, Tatti M, Arancia G, Crateri P, Vaccaro AM. Saposin D solubilizes anionic phospholipid-containing membranes. J Biol Chem. 2001;276:31583\u20139.","journal-title":"J Biol Chem"},{"key":"1858_CR45","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.4161\/cc.21127","volume":"11","author":"AK McClendon","year":"2012","unstructured":"McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, et al. CDK4\/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012;11:2747\u201355.","journal-title":"Cell Cycle"},{"key":"1858_CR46","doi-asserted-by":"publisher","first-page":"29075","DOI":"10.1074\/jbc.M112.365494","volume":"287","author":"JL Dean","year":"2012","unstructured":"Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4\/6 inhibition. J Biol Chem. 2012;287:29075\u201387.","journal-title":"J Biol Chem"},{"key":"1858_CR47","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djs002","volume":"104","author":"PJ Roberts","year":"2012","unstructured":"Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, et al. Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012;104:476\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"1858_CR48","doi-asserted-by":"crossref","unstructured":"Delgado M, Chambers TC. Microtubules play an essential role in the survival of primary acute lymphoblastic leukemia cells advancing through G1 phase. Cell Cycle. 2018;17:1784\u201396.","DOI":"10.1080\/15384101.2018.1496746"},{"key":"1858_CR49","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","volume":"37","author":"B Salvador-Barbero","year":"2020","unstructured":"Salvador-Barbero B, \u00c1lvarez-Fern\u00e1ndez M, Zapatero-Solana E, El Bakkali A, Men\u00e9ndez MDC, L\u00f3pez-Casas PP, et al. CDK4\/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell. 2020;37:340\u201353.e6.","journal-title":"Cancer Cell"},{"key":"1858_CR50","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-18-0790","volume":"25","author":"AS Clark","year":"2019","unstructured":"Clark AS, McAndrew NP, Troxel A, Feldman M, Lal P, Rosen M, et al. Combination paclitaxel and palbociclib: results of a phase I trial in advanced breast cancer. Clin Cancer Res. 2019;25:2072\u20139.","journal-title":"Clin Cancer Res"},{"key":"1858_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104106","volume":"10","author":"KH Kim","year":"2025","unstructured":"Kim KH, Park C, Beom SH, Kim MH, Kim CG, Kim HR, et al. An open-label, phase IB\/II study of abemaciclib with paclitaxel for tumors with CDK4\/6 pathway genomic alterations. ESMO Open. 2025;10:104106.","journal-title":"ESMO Open"},{"key":"1858_CR52","doi-asserted-by":"publisher","first-page":"13030","DOI":"10.1021\/acs.jmedchem.5c01058","volume":"68","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yin F, Luo Z, Zheng Y, Guo S, Wu S, et al. Design and synthesis of PARP\/CDK6 dual-target inhibitors modulating of Wnt\/\u03b2-catenin signaling pathway for the treatment of BRCA wild-type TNBC. J Med Chem. 2025;68:13030\u201356.","journal-title":"J Med Chem"},{"key":"1858_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.068","volume":"31","author":"J Romero-Pozuelo","year":"2020","unstructured":"Romero-Pozuelo J, Figlia G, Kaya O, Martin-Villalba A, Teleman AA. Cdk4 and Cdk6 couple the cell-cycle machinery to cell growth via mTORC1. Cell Rep. 2020;31:107504.","journal-title":"Cell Rep"},{"key":"1858_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","volume":"29","author":"S Goel","year":"2016","unstructured":"Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors. Cancer Cell. 2016;29:255\u201369.","journal-title":"Cancer Cell"},{"key":"1858_CR55","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","volume":"28","author":"SM Tolaney","year":"2022","unstructured":"Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, et al. Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant. Clin Cancer Res. 2022;28:1500\u20136.","journal-title":"Clin Cancer Res"},{"key":"1858_CR56","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","volume":"34","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Su F, Solovieff N, Hortobagyi G, Chia S, Neven P, et al. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann Oncol. 2023;34:1003\u201314.","journal-title":"Ann Oncol"},{"key":"1858_CR57","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41416-024-02852-y","volume":"131","author":"D Prasad","year":"2024","unstructured":"Prasad D, Baldelli E, Blais EM, Davis J, El Gazzah E, Mueller C, et al. Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort. Br J Cancer. 2024;131:1543\u201354.","journal-title":"Br J Cancer"},{"key":"1858_CR58","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nature02866","volume":"431","author":"SH Um","year":"2004","unstructured":"Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431:200\u20135.","journal-title":"Nature"},{"key":"1858_CR59","doi-asserted-by":"publisher","first-page":"35375","DOI":"10.1074\/jbc.M806480200","volume":"283","author":"J Zhang","year":"2008","unstructured":"Zhang J, Gao Z, Yin J, Quon MJ, Ye J. S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2. J Biol Chem. 2008;283:35375\u201382.","journal-title":"J Biol Chem"},{"key":"1858_CR60","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","volume":"4","author":"N Chalhoub","year":"2009","unstructured":"Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127\u201350.","journal-title":"Annu Rev Pathol"},{"key":"1858_CR61","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1634\/theoncologist.12-8-1007","volume":"12","author":"X Wan","year":"2007","unstructured":"Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007;12:1007\u201318.","journal-title":"Oncologist"},{"key":"1858_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22:138.","journal-title":"Mol Cancer"},{"key":"1858_CR63","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.1199498","volume":"332","author":"PP Hsu","year":"2011","unstructured":"Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332:1317\u201322.","journal-title":"Science"},{"key":"1858_CR64","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10:1174\u201393.","journal-title":"Cancer Discov"},{"key":"1858_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45835-6","volume":"15","author":"J G\u00f3mez Tejeda Za\u00f1udo","year":"2024","unstructured":"G\u00f3mez Tejeda Za\u00f1udo J, Barroso-Sousa R, Jain E, Jin Q, Li T, Buendia-Buendia JE, et al. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic\/transcriptomic determinants of resistance in a phase I\/II trial. Nat Commun. 2024;15:2446.","journal-title":"Nat Commun"},{"key":"1858_CR66","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.3390\/cells11233834","volume":"11","author":"T Siddika","year":"2022","unstructured":"Siddika T, Balasuriya N, Frederick MI, Rozik P, Heinemann IU, O\u2019Donoghue P. Delivery of active AKT1 to human cells. Cells. 2022;11:3834.","journal-title":"Cells"},{"key":"1858_CR67","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/iub.2826","volume":"76","author":"T Siddika","year":"2024","unstructured":"Siddika T, Shao R, Heinemann IU, O\u2019Donoghue P. Delivery of AKT1 phospho-forms to human cells reveals differential substrate selectivity. IUBMB life. 2024;76:632\u201346.","journal-title":"IUBMB life"},{"key":"1858_CR68","doi-asserted-by":"publisher","first-page":"e1010110","DOI":"10.1371\/journal.pcbi.1010110","volume":"18","author":"BM Invergo","year":"2022","unstructured":"Invergo BM. Accurate, high-coverage assignment of in vivo protein kinases to phosphosites from in vitro phosphoproteomic specificity data. PLoS Comput Biol. 2022;18:e1010110.","journal-title":"PLoS Comput Biol"},{"key":"1858_CR69","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201911036","volume":"219","author":"Q Yin","year":"2020","unstructured":"Yin Q, Jian Y, Xu M, Huang X, Wang N, Liu Z, et al. CDK4\/6 regulate lysosome biogenesis through TFEB\/TFE3. J Cell Biol. 2020;219:e201911036.","journal-title":"J Cell Biol"},{"key":"1858_CR70","doi-asserted-by":"publisher","first-page":"43678","DOI":"10.18632\/oncotarget.18435","volume":"8","author":"ES Knudsen","year":"2017","unstructured":"Knudsen ES, Hutcheson J, Vail P, Witkiewicz AK. Biological specificity of CDK4\/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017;8:43678\u201391.","journal-title":"Oncotarget"},{"key":"1858_CR71","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1242\/jcs.146365","volume":"129","author":"G Napolitano","year":"2016","unstructured":"Napolitano G, Ballabio A. TFEB at a glance. J Cell Sci. 2016;129:2475\u201381.","journal-title":"J Cell Sci"},{"key":"1858_CR72","doi-asserted-by":"publisher","first-page":"ra42","DOI":"10.1126\/scisignal.2002790","volume":"5","author":"A Roczniak-Ferguson","year":"2012","unstructured":"Roczniak-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5:ra42.","journal-title":"Sci Signal"},{"key":"1858_CR73","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/ncb3407","volume":"18","author":"Y Li","year":"2016","unstructured":"Li Y, Xu M, Ding X, Yan C, Song Z, Chen L, et al. Protein kinase C controls lysosome biogenesis independently of mTORC1. Nat Cell Biol. 2016;18:1065\u201377.","journal-title":"Nat Cell Biol"},{"key":"1858_CR74","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1042\/BJ20150404","volume":"470","author":"C Stretton","year":"2015","unstructured":"Stretton C, Hoffmann TM, Munson MJ, Prescott A, Taylor PM, Ganley IG, et al. GSK3-mediated raptor phosphorylation supports amino-acid-dependent mTORC1-directed signalling. Biochem J. 2015;470:207\u201321.","journal-title":"Biochem J"},{"key":"1858_CR75","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1038\/onc.2014.390","volume":"34","author":"I Azoulay-Alfaguter","year":"2015","unstructured":"Azoulay-Alfaguter I, Elya R, Avrahami L, Katz A, Eldar-Finkelman H. Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. Oncogene. 2015;34:4613\u201323.","journal-title":"Oncogene"},{"key":"1858_CR76","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1080\/15548627.2016.1271514","volume":"13","author":"S Vega-Rubin-de-Celis","year":"2017","unstructured":"Vega-Rubin-de-Celis S, Pe\u00f1a-Llopis S, Konda M, Brugarolas J. Multistep regulation of TFEB by MTORC1. Autophagy. 2017;13:464\u201372.","journal-title":"Autophagy"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01858-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:02:54Z","timestamp":1787043774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01858-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1858"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01858-x","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}